MapLight Therapeutics, Inc. MPLT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $172.25M+24.5% | $138.35M+46.5% | $94.44M+12.2% | $84.16M— | —— | ||
| $37.8M+23.0% | $30.73M+119% | $14.04M+2.4% | $13.72M— | —— | ||
| $210.04M+24.2% | $169.08M+55.9% | $108.48M+10.8% | $97.88M— | —— | ||
| -$210.04M-24.2% | -$169.08M-55.9% | -$108.48M-10.8% | -$97.88M— | —— | ||
| $8.9M+12.2% | $7.93M+40.4% | $5.65M+3.7% | $5.45M— | —— | ||
| -$199.48M-23.8% | -$161.15M-56.7% | -$102.83M-11.3% | -$92.43M-14.1% | -$80.99M-4.4% | ||
| —— | —— | —— | —— | —— | ||
| -$209.47M-24.3% | -$168.51M-56.2% | -$107.85M-11.0% | -$97.15M— | —— | ||
| -$210.04M-24.2% | -$169.08M-55.9% | -$108.48M-10.8% | -$97.88M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is MapLight Therapeutics, Inc. profitable?
- MapLight Therapeutics, Inc. is not currently profitable: it reported a net loss of $199.5M over the trailing twelve months.
- What is MapLight Therapeutics, Inc. 's earnings per share?
- MapLight Therapeutics, Inc. 's diluted EPS over the trailing twelve months is $-95.86.
- Where does MapLight Therapeutics, Inc. 's income statement data come from?
- Every line is extracted from MapLight Therapeutics, Inc. 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.